Background: Lorlatinib and crizotinib are oral tyrosine kinase inhibitors with activity against ALK and ROS1 fusion proteins. Crizotinib is well tolerated and has superior efficacy compared to chemotherapy for treatment of patients with advanced ALK + nonsmall-cell lung cancer (NSCLC). However, resistance to crizotinib can develop, and the central nervous system (CNS) is often a site of disease relapse. Second-generation ALK inhibitors, ceritinib and alectinib, have demonstrated activity in crizotinib-naive or resistant treatment settings, and alectinib has been shown to have superior progression-free survival (PFS) compared to crizotinib as first-line therapy. Lorlatinib is a selective, CNS-penetrant ALK inhibitor that has potent activity against ALK and kinase domain resistance mutations, including the difficult-to-treat G1202R mutation.Lorlatinib has shown clinical activity in patients previously treated with crizotinib and other ALK inhibitors, including patients with progressive CNS metastases. This study aims to determine if lorlatinib is superior to crizotinib in prolonging PFS in treatment-naïve patients and to identify candidate biomarkers predictive of clinical efficacy or treatment resistance. Method: Trial Design This global, multicenter, open-label phase 3 study will enroll w280 treatment-naïve patients. Eligible patients must be aged 18 years, have Eastern Cooperative Oncology Group performance status of 0e2 and 1 measurable extracranial target lesion not previously treated with radiotherapy. Patients with asymptomatic brain metastases are eligible. Patients will be randomized (1:1) to lorlatinib 100 mg once daily or crizotinib 250 mg twice daily and stratified by presence of brain metastases (yes/no) and ethnicity (Asian/non-Asian). Treatment will continue until disease progression, patient refusal, or unacceptable toxicity. Crossover between treatment arms will not be permitted. The primary endpoint is PFS based on blinded independent central review (BICR) using RECIST v1.1. Secondary endpoints include PFS based on investigator assessment, overall survival, objective response (OR) by BICR and investigator assessment; intracranial (IC) OR (periodic magnetic resonance imaging will be performed for central nervous system evaluation), IC time to progression, duration of response and time to response all by BICR; tumor tissue and peripheral blood circulating free DNA biomarker assessment, adverse events and patient-re- The ALK inhibitors, such as crizotinib and alectinib show a great response to patients with non-small cell lung cancer (NSCLC) harboring ALK fusions. However, the acquired drug resistance is also known as important issues in the treatment with the specific molecular targeted agents, such as EGFR-TKI as well as ALK-TKI. The mechanisms of acquired resistance to ALK-TKI are reported previously, bypass tract signals of EGFR or MET, and Epithelial-mesenchymal transition (EMT). Novel generation ALK inhibitor brigatinib is promising for NSCLC harboring ALK fusions, however, the precise mechanism of the acquired resistance to brigatinib is not fully understood. To elucidate for the novel acquired resistance to brigatinib, we here conducted the cell-based experiments using ALK fusion NSCLC cells. Method: We established ALK fusion NSCLC cells H3122 (variant 1 E13;A20) and H2228 (variant 3 E6; A20) with the acquired resistance to brigatinib by step-wise methods. ALK inhibitor sensitivity and signal transduction in H3122 and H2228 cells were examined in vitro. Result: H3122-brigatinib resistance cell (H3122-BR) and H2228brigatinib resistance cell (H2228-BR) indicated the cross-resistance to other ALK inhibitors alectinib, crizotinib and lorlatinib. Furthermore, morphological change was observed to spindle shape, and additionally shows decreasing of E-cadherin and increasing of vimentin which are marker of EMT by the western blotting analysis. Moreover, some of these resistant cells cultured with drug-free medium for 4weeks were reversed the sensitivity to ALK-TKIs and cell formation backed to parental cells. Conclusion: We demonstrated that EMT elicited the acquired resistance to ALK-TKIs under the exposure of brigatinib treatment in ALK fusion NSCLC cells. Further experiments are needed to overcome this drug resistance induced by EMT. Keywords: epithelial-mesenchymal transition, ALK, Acquired resistance P1.13-08 Distribution, Differences in Clinical Characteristics and Resistance Mechanism of ALK Variants in Chinese Lung Cancer Patients
